Table 2 Prior studies examining SRS for brainstem metastases
Study | Treatment modality | Patients, n | Mean age, y | Median tumor volume, mL | Median prescribed SRS Dose, Gy | Median survival, mo | Local tumor control, % | Factors associated With shorter survival | Complication rate |
|---|---|---|---|---|---|---|---|---|---|
Huang et al. [8] | Gamma Knife | 26 | 56 | 1.1 | 16 | 9 | 95 | Presence of active extracranial disease | 27% |
Shuto et al. [13] | Gamma Knife | 25 | 57.1 | 2.1 (mean) | 13 (mean) | 4.9 | 77 | N/A | 8% |
Fuentes et al. [6] | Gamma Knife | 28 | 57.7 | 2.1 (mean) | 19.6 (mean) | 12 | 92 | N/A | 0% |
Yen et al. [14] | Gamma Knife | 53 | 57.3 | 2.8 (mean) | 17.6 (mean) | 11 | 87 | Presence of extracranial disease | 0% |
Hussain et al. [9] | Gamma Knife | 22 | 60 (median) | 0.9 | 16 | 8.5 | 100 | N/A | 5% |
Kased et al. [10] | Gamma Knife | 42 | 55 (median) | 0.26 | 16 | 9 | 85 | Multiple metastases, melanoma primary | 10% |
Lorenzoni et al. [15] | Gamma Knife | 25 | 54 | 0.6 (mean) | 20 (mean) | 11.1 | 95 | KPS <80, uncontrolled primary tumor, radiotherapy, SRS < 18 Gy | 0% |
Koyfman et al. [11] | Gamma Knife | 43 | 59 (median) | 0.37 | 15 | 5.8 | 85 | Lower KPS, larger tumor volume, SIR, GPA | 12% |
Hatiboglu et al. [7] | Linac-based SRT/SRS | 60 | 61 (median) | 1 | 15 | 4.2 | 76 | Tumor volume ≥4 mL, male sex | 20% |
Lin et al. [12] | Linac-based SRT/SRS | 45 | 59.9 | 0.4 | 14 | 11.6 | 91 | Lower KPS | 4% |
Present Study | Linac-based SRT/SRS | 36 | 61 | 0.94 | 17 | 3 | 93 | Lower GPA, lower prescription dose, fewer fractions | 8% |